Objective: Adaptive Software as Medical Devices (SaMDs) are revolutionizing the management of metabolic diseases like diabetes and obesity through real-time analytics and AI-driven clinical support. However, rapidly evolving regulations pose challenges for clinics, patient safety, and innovation. As the global impact of diabetes and obesity grows, there is a notable gap in understanding regulatory pathways, clinical trial rigor, and post-market safety for adaptive SaMDs. This research analyzes the clearance processes, clinical evidence's quality, and SaMDs' safety profiles designed for diabetes and obesity management, focusing on insulin dosing algorithms and continuous glucose monitoring.
Methods: A review of FDA and EMA databases from January 2004 to December 2024, emphasizing US FDA approvals, we identified 23 SaMDs that met our criteria.
Results: Our findings revealed, nearly all SaMDs cleared through 510(k) pathways, primarily classified as Class II devices (96%). Approval times typically ranged from 12-18 months, with adaptations requiring an additional 6-12 months. While clinical trials were multicenter and focused on adults aged between 18 to 64 years, and there was limited representation of pediatric populations.
Conclusion: Key safety concerns included severe hypoglycaemia (2 to 5 episodes per 100 patient years) and device malfunctions, which led to recalls. Moving forward, addressing regulatory differences, enhancing pediatric studies, and reinforcing cybersecurity measures will be essential. Robust post-market surveillance and aligned global regulations are crucial for ensuring safe and equitable access to these innovative tools. Future research should delve into long-term outcomes and real-world effectiveness to unlock the full potential of adaptive SaMDs.
Keywords: Software as Medical Device, Diabetes management, Obesity, FDA 510(k) clearance, Adaptive algorithms, Continuous glucose monitoring
How to cite this article: Talari S, Jupudi S, Kumar GKP, Kuppusamy G, The Regulatory Pathways And Safety Profiles Of Software As Medical Devices For Diabetes And Obesity In Metabolic Disease Management. Int J Drug Deliv Technol. 2026;16(4s): 573-587; DOI: 10.25258/ijddt.16.4s.67
Source of support: Nil
Conflict of interest: None